Celecoxib, a Cox2 inhibitors, was shown to decrease MDSC recruitment and increased CD8+ T cell tumor infiltration in gliomas and colon carcinoma by decreasing CCL2 production (170). Here, CD8A is linked to central nervous system cancer.